BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 10958767)

  • 21. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation.
    Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Wakabayashi T; Sawabu N
    J Gastroenterol; 2002; 37(10):831-9. PubMed ID: 12424567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.
    Li ZH; Zheng J; Weiss LM; Shibata D
    Am J Pathol; 1994 Feb; 144(2):303-9. PubMed ID: 8311114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
    Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
    Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
    Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
    J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients.
    Gao W; Mady HH; Melhem MF; Keohavong P
    Mol Carcinog; 2009 Jul; 48(7):633-41. PubMed ID: 19072763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
    Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of mutation types of p53 gene and possible carcinogenic factors in lung cancer].
    Gao ZQ; Gao Z; Zhang X
    Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Mar; 31(2):88-91. PubMed ID: 9812619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique.
    Behn M; Qun S; Pankow W; Havemann K; Schuermann M
    Clin Cancer Res; 1998 Feb; 4(2):361-71. PubMed ID: 9516924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of cancerous endobronchial lesions by autofluorescence bronchoscopy combined with mutation analysis of p53.
    Lang SM; Ebelt K; Hautmann H; Stratakis DF; Huber RM
    Eur J Med Res; 2005 Jul; 10(7):273-7. PubMed ID: 16055396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
    Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
    Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
    Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
    Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
    Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
    Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations.
    Marchetti A; Pellegrini S; Bertacca G; Buttitta F; Gaeta P; Carnicelli V; Nardini V; Griseri P; Chella A; Angeletti CA; Bevilacqua G
    J Pathol; 1998 Mar; 184(3):240-6. PubMed ID: 9614374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.